Dogwood Therapeutics, Inc. (DWTX) Stock Ticker
Market factors today
Unlock the full DWTX picture
About Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
DWTX stock facts
| Ticker symbol | DWTX |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $45.7M |
| CEO | Gregory Duncan |
| Employees | 8 |
| Headquarters | Alpharetta, GA, US |
| IPO date | 2020-12-17 |
| Website | www.dwtx.com |
What you can see for DWTX on Tickr
Live DWTX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the DWTX report.
Rankings
FAQ
What is the ticker symbol for Dogwood Therapeutics, Inc.?
The ticker symbol for Dogwood Therapeutics, Inc. is DWTX, listed on the NASDAQ Capital Market.
What is DWTX?
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company…